CL2022000757A1 - Tienopirimidonas como inhibidores de trpa1 - Google Patents

Tienopirimidonas como inhibidores de trpa1

Info

Publication number
CL2022000757A1
CL2022000757A1 CL2022000757A CL2022000757A CL2022000757A1 CL 2022000757 A1 CL2022000757 A1 CL 2022000757A1 CL 2022000757 A CL2022000757 A CL 2022000757A CL 2022000757 A CL2022000757 A CL 2022000757A CL 2022000757 A1 CL2022000757 A1 CL 2022000757A1
Authority
CL
Chile
Prior art keywords
thienopyrimidones
trpa1 inhibitors
inhibitors
diseases
trpa1
Prior art date
Application number
CL2022000757A
Other languages
English (en)
Inventor
Georg Dahmann
Joerg P Hehn
Martin Thomas Fleck
Florian Paul Christian Binder
Annekatrin Charlotte Heimann
Uta Friederike Lessel
Jens Willwacher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2022000757A1 publication Critical patent/CL2022000757A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a tienopirimidinonas y a su uso como inhibidores de la actividad de TRPA1, a composiciones farmacéuticas que las contienen, y a métodos para usarlas como agentes para el tratamiento y/o la prevención de enfermedades fibróticas, enfermedades inflamatorias y autoinmunitarias y enfermedades relacionadas con el SNC.
CL2022000757A 2019-10-15 2022-03-25 Tienopirimidonas como inhibidores de trpa1 CL2022000757A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19203173 2019-10-15

Publications (1)

Publication Number Publication Date
CL2022000757A1 true CL2022000757A1 (es) 2023-01-20

Family

ID=68289874

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000757A CL2022000757A1 (es) 2019-10-15 2022-03-25 Tienopirimidonas como inhibidores de trpa1

Country Status (14)

Country Link
US (2) US20210107919A1 (es)
EP (1) EP4045144A1 (es)
JP (1) JP7354438B2 (es)
KR (1) KR20220084127A (es)
CN (1) CN114945408B (es)
AR (1) AR120221A1 (es)
AU (1) AU2020366678A1 (es)
BR (1) BR112022003729A2 (es)
CA (1) CA3153115A1 (es)
CL (1) CL2022000757A1 (es)
IL (1) IL292095A (es)
MX (1) MX2022004564A (es)
TW (1) TW202128705A (es)
WO (1) WO2021074197A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
CA2820448A1 (en) * 2010-12-20 2012-06-28 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
WO2012172475A1 (en) * 2011-06-13 2012-12-20 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using trpa1 antagonists
JP6573968B2 (ja) * 2014-08-11 2019-09-11 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体
US12006328B2 (en) * 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
WO2017060488A1 (en) * 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists

Also Published As

Publication number Publication date
US20210395267A1 (en) 2021-12-23
EP4045144A1 (en) 2022-08-24
CN114945408B (zh) 2024-04-16
CA3153115A1 (en) 2021-04-22
WO2021074197A1 (en) 2021-04-22
KR20220084127A (ko) 2022-06-21
CN114945408A (zh) 2022-08-26
JP7354438B2 (ja) 2023-10-02
JP2022551956A (ja) 2022-12-14
US11578080B2 (en) 2023-02-14
TW202128705A (zh) 2021-08-01
IL292095A (en) 2022-06-01
MX2022004564A (es) 2022-05-06
US20210107919A1 (en) 2021-04-15
BR112022003729A2 (pt) 2022-05-31
AR120221A1 (es) 2022-02-02
AU2020366678A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
CO2017011851A2 (es) Compuestos novedosos
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
AR128259A2 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
CL2021002882A1 (es) Inhibidores de fgfr y métodos de uso de los mismos
CR20180029A (es) Inhibidores peotídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
UY36215A (es) Espirocicloheptanos como inhibidores de rock
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CR20190394A (es) Compuestos de inhibidores de autotaxina
AR103895A1 (es) Lactamas como inhibidores de rock
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35357A (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa n eutrofílica
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CO2017000745A2 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila